预约演示
更新于：2026-09-07
Glipizide/Metformin Hydrochloride
格列吡嗪/盐酸二甲双胍
更新于：2026-09-07
概要
基本信息
药物类型 小分子化药 |
别名 Compound Metformin Hydrochloride and Glipizide、Glipizide/metformin、Metaglip + [6] |
作用方式 激动剂、调节剂 |
作用机制 AMPK激动剂(AMP活化蛋白激酶激动剂)、SUR调节剂(磺酰脲受体调节剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2002-10-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H39ClN10O4S |
InChIKeyFMUIDSCDMUNUQP-UHFFFAOYSA-N |
CAS号869289-66-7 |
关联
16
项与 格列吡嗪/盐酸二甲双胍 相关的临床试验CTR20241285
评估受试制剂二甲双胍格列吡嗪片（规格：250 mg/2.5 mg）与参比制剂二甲双胍格列吡嗪片（规格：250 mg/2.5 mg）在健康成年受试者空腹和餐后状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性研究。
CTR20231729
二甲双胍格列吡嗪胶囊人体生物等效性研究
CTR20230663
二甲双胍格列吡嗪片在空腹及餐后条件下的人体生物等效性试验
100 项与 格列吡嗪/盐酸二甲双胍 相关的临床结果
登录后查看更多信息
100 项与 格列吡嗪/盐酸二甲双胍 相关的转化医学
登录后查看更多信息
100 项与 格列吡嗪/盐酸二甲双胍 相关的专利（医药）
登录后查看更多信息
2
项与 格列吡嗪/盐酸二甲双胍 相关的文献（医药）2012-01-01Advances in therapy3区 · 医学
Fixed-Dose Combinations for Treatment of Type 2 Diabetes Mellitus
3区 · 医学
Review
作者: Blonde, Lawrence ; San Juan, Zinnia T.
INTRODUCTION:
Combining antihyperglycemic agents with complementary mechanisms of action is a cornerstone of type 2 diabetes mellitus (T2DM) management. Although several fixed-dose combinations (FDCs) are available, representing standard types of combination therapy in T2DM, use of these products has been limited.
METHODS:
To address the likely concerns of prescribers and patients regarding the use of FDCs in the treatment of T2DM, literature searches were performed to ascertain the bioavailability, efficacy, tolerability, and cost-effectiveness of the currently approved FDCs compared with their individual component drugs given as separate pills in combination. Additionally, data were collected on rates of adherence, clinical outcomes, and overall treatment costs with FDCs versus dual therapy with the same constituent drugs.
RESULTS:
Bioavailability is equivalent for FDCs and dual therapy used in T2DM. Efficacy and tolerability also appear to be at least as good with FDCs as with dual therapy. Retrospective analyses have suggested that FDCs can enhance adherence to therapy, presumably as a result of the reduction in pill burden, and improved adherence may result in improved glycemic control and reduced disease management costs. In addition, because currently available FDCs come in two or more dose-strength formulations, they also afford some measure of dosing flexibility.
CONCLUSIONS:
The available evidence supports the wider use of FDCs in the treatment of patients with T2DM.
2008-07-01Journal of diabetes science and technology
Spending for Diabetes Drugs is Increasing in the United States
作者: Klonoff, David C.
As of 2007, the treatment of diabetes has become the leading source of increased spending on prescription drugs. This was reported by Medco Health Solutions Inc. in its 2008 Drug Trend Report, a comprehensive analysis of prescription drug spending and utilization.1 In 2007, diabetes drugs accounted for 7% of prescription drug spending in the United States (U.S.). See Table 1.
Table 1
Top Therapeutic Categories Contributing to Drug Spending by Medco in 20071
Diabetes drugs had the distinction of contributing 20.6% to the overall 2.0% rise in prescription medication costs to Medco. Diabetes is now first on the list of the ten greatest contributors to the upward trend in prescription costs. The top 13 diseases in descending order are currently (1) diabetes, (2) respiratory diseases, (3) cancer and transplants, (4) rheumatologic diseases, (5) seizures, (6) viral infections, (7) Alzheimer's and Parkinson's Disease, (8) psychosis, (9) urologic diseases, (10) dermatologic diseases, (11) pain requiring non-narcotic relief, (12) depression, and (13) hyperlipidemia. The basis of this report is benefit data from Medco, the nation's leading pharmacy benefit manager. The data are from Medco's 2007 total net revenues of more than $44 billion, which go toward prescription drug benefit programs for one-in-five Americans.
The overall increase in spending on prescription drugs was low, at 2.0%, during the past year, which the report defined as between 2006–2007. The increase in spending on diabetes drugs increased because of a combination of factors. The number of patients using diabetes drugs increased only slightly, by 2.3%; however, the sharp increase of 9.5% in the unit cost per drug per patient and the large number of patients with coverage for diabetes combined to generate a 12% increase in spending on diabetes drugs. The increased cost per patient can be attributed to a combination of an increased number of patients, a rise in prices of brand-name drugs, and a migration of patients receiving treatment toward newer more expensive drugs.
Increased use of various synthetic insulin products, such as rapid-acting analogs, including Apidra® (sanofi-aventis), Humalog® (Eli Lilly), and NovoLog® (Novo Nordisk), and long-acting analogs, such as Lantus® (sanofi-aventis), and Levemir (Novo Nordisk), contributed to the trend in increased spending. Total sales of Exubera® (Pfizer), which was withdrawn from the market in late 2007, contributed very little to overall spending on insulin products. The unit cost of insulin, which also reflects some migration from insulin vials to insulin pens, increased by 14.5% last year. This rise outstripped the increase in the unit costs of oral agents.
Among noninsulin hypoglycemic agents, utilization growth was led by Januvia™ (Merck), which was launched in December 2006. Byetta (Amylin Pharmaceuticals), which was launched in April 2005, also contributed to increased spending in this category. Two recently approved oral combination drugs also added to the growth of this category: ACTOplus met™ (Takeda), launched in August 2005, and Avandaryl® (GlaxoSmithKline), launched in June 2006. Increased spending for all of these drugs offset the decline in sales of Avandia® (GlaxoSmithKline), following release of evidence that use of this drug was linked to cardiovascular disease.2 Despite a decline in the unit cost for many generic diabetes drugs, overall spending on generic drugs increased by 8.7%.
The Medco report went on to predict that over the next three years, from 2008 to 2010, spending on diabetes drugs would increase by 8%. Such an increase for diabetes would be second only to that for lipid-lowering drugs. New drugs in the pipeline that are likely to be submitted to the Food and Drug Administration for approval include agents from the glucagon-like peptide-1 and dipeptidyl peptidase-4 inhibitor families. Also a combination drug containing nateglinide and valsartan is under development.
Future spending trends for diabetes will likely be affected by multiple factors. Newly approved drugs for diabetes and obesity will probably be expensive. New indications for selected existing diabetes drugs, such as the prevention of diabetes or obesity, will increase use of these products. New dosage forms, such as alternate routes of insulin administration, will offer convenience and possibly better predictability of absorption, but at a cost.3 New combination products might be released and the costs of these products compared to those of their components might increase or decrease spending for these drugs. Patent expirations and first-time generic introductions will lower overall spending for diabetes drugs. The next diabetes drug whose patent is scheduled to end will be Prandin® (Novo Nordisk) in 2009. Drugs can become approved for over-the-counter use and this tends to lower the necessary spending for the drugs by prescription plans because the expense is generally shifted to the patient. New research and clinical recommendations will affect prescribing patterns and can increase or decrease the costs of prescriptions. Recently reported evidence has demonstrated that colesevelam may improve glycemic control as well as reduce LDL-cholesterol levels in patients with type 2 diabetes receiving sulfonylurea-based therapy.4 Finally, the increasing prevalence of diabetes that is expected in the next few years will increase utilization of and spending on diabetes drugs.
The use of generic drugs can reduce the cost of medications while continuing to provide effective care. Generics can provide the safety and efficacy of brand-name products at a lower cost.5 Before a patent on a drug expires and it is produced generically, a pharmaceutical company may launch a newer brand name product containing the same basic ingredient. To extend the patent life of an existing compound, a manufacturer may choose to adopt one or more of the following six approaches:
Develop a once-daily, extended-release version of a product. This approach was used for Glucotrol® XL (Pfizer) and Glynase® PresTab® (Pfizer).
Introduce a new combination product. This approach was used for Glucovance® (Bristol-Myers Squibb), Avandamet® (GlaxoSmithKline), Metaglip™ (Bristol-Myers Squibb), ACTOplus met (Takeda), Avandaryl (GlaxoSmithKline), Janumet™ (Merck), and Prandimet™ (Novo Nordisk).
Obtain a new indication for a product and market it under a different brand name. This approach was used for Revatio® (Pfizer) for pulmonary arterial hypertension, which contains the same active ingredient as Viagra® (Pfizer), but was approved for a different indication at a different dose and strength.
Add another molecule to the basic drug to extend its half-life. This approach was being considered by Nektar for developing a long-acting form of Exubera (Pfizer).
Develop a single-isomer version of a racemic compound. This approach is being considered for thiazolidinedione products that are currently on the market, such as Actos® (Takeda) and Avandia (GlaxoSmithKline).6
Introduce an active metabolite of an existing product. This approach is being studied for Combrestatin-A4.7 This compound is a potential antihyperglycemic agent, and it is the active metabolite of Zybrestat™ (OXiGENE), which is being developed as a chemotherapeutic agent.
At this time, there is plenty of room for improvement in the control of diabetes in the U.S. The latest data from the National Health and Nutrition Examination Survey, reported in April 2008, indicated that between 1999 and 2004, the age-adjusted percentage of people with diagnosed diabetes achieving a hemoglobin A1c target level of <7.0% was 57.1%.8 In type 1 diabetes, additional drug delivery methods are needed and in type 2 diabetes additional drugs are needed for those patients who cannot achieve adequate results from a healthy diet and regular exercise. Such new drug delivery systems and drugs are in the pipeline. In spite of strong evidence that a healthy diet and exercise program can decrease the incidence of diabetes,9 diabetes is likely to become more prevalent in the U.S. The number of affected adult patients is likely to climb from the current estimated number, 20.6 million, which is 9.6% of the adults in the U.S.,10 to as many as 37.7 million by 2031, which would be 14.5% of the projected adult population.11 It is very likely that spending on drugs for diabetes will continue to increase.
100 项与 格列吡嗪/盐酸二甲双胍 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 2型糖尿病 | 美国 | 2002-10-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 40 | (Glipizide Metformin) | 糧繭築網網夢範蓋艱鏇(網網壓簾憲糧鹹襯願顧) = 選鏇膚範觸膚鏇構鏇夢 鏇願廠構簾蓋衊構襯積 (觸選廠窪願選鏇鑰觸範, 92.6166) 更多 | - | 2009-08-18 | |
(Metaglip™) | 糧繭築網網夢範蓋艱鏇(網網壓簾憲糧鹹襯願顧) = 窪鑰鏇齋範鑰築鏇簾製 鏇願廠構簾蓋衊構襯積 (觸選廠窪願選鏇鑰觸範, 96.1909) 更多 | ||||||
临床1期 | - | 40 | (Glipizide Metformin) | 餘壓淵鬱願壓遞鏇願製(壓繭遞願遞壓蓋窪構遞) = 構蓋淵襯鏇鬱遞願襯積 積鏇構鹽鬱糧構鑰鑰淵 (壓膚艱艱蓋蓋範選壓餘, 69.6511) 更多 | - | 2009-08-18 | |
(Metaglip®) | 餘壓淵鬱願壓遞鏇願製(壓繭遞願遞壓蓋窪構遞) = 構願網鑰選願糧夢淵廠 積鏇構鹽鬱糧構鑰鑰淵 (壓膚艱艱蓋蓋範選壓餘, 94.7365) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用